JP7440940B2 - Ｐｌｋ１の選択的分解誘導化合物 - Google Patents

Ｐｌｋ１の選択的分解誘導化合物 Download PDF

Info

Publication number
JP7440940B2
JP7440940B2 JP2021578216A JP2021578216A JP7440940B2 JP 7440940 B2 JP7440940 B2 JP 7440940B2 JP 2021578216 A JP2021578216 A JP 2021578216A JP 2021578216 A JP2021578216 A JP 2021578216A JP 7440940 B2 JP7440940 B2 JP 7440940B2
Authority
JP
Japan
Prior art keywords
mmol
amino
methyl
synthesis
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021578216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539579A (ja
JP2022539579A5 (cg-RX-API-DMAC10.html
Inventor
チェ，シウ
リュ，スーヒー
リュ，チフン
ソン，サンハ
リ，ファジン
キム，ソンフン
ナム，ボアス
ミン，インスク
リュ，ヒェグク
カン，クムヤン
Original Assignee
オップテラ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オップテラ インコーポレイテッド filed Critical オップテラ インコーポレイテッド
Publication of JP2022539579A publication Critical patent/JP2022539579A/ja
Publication of JP2022539579A5 publication Critical patent/JP2022539579A5/ja
Priority to JP2023177565A priority Critical patent/JP2023171659A/ja
Application granted granted Critical
Publication of JP7440940B2 publication Critical patent/JP7440940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021578216A 2020-03-27 2021-03-27 Ｐｌｋ１の選択的分解誘導化合物 Active JP7440940B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023177565A JP2023171659A (ja) 2020-03-27 2023-10-13 Ｐｌｋ１の選択的分解誘導化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200037875 2020-03-27
KR10-2020-0037875 2020-03-27
PCT/KR2021/003807 WO2021194318A1 (en) 2020-03-27 2021-03-27 Plk1 selective degradation inducing compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023177565A Division JP2023171659A (ja) 2020-03-27 2023-10-13 Ｐｌｋ１の選択的分解誘導化合物

Publications (3)

Publication Number Publication Date
JP2022539579A JP2022539579A (ja) 2022-09-12
JP2022539579A5 JP2022539579A5 (cg-RX-API-DMAC10.html) 2023-03-29
JP7440940B2 true JP7440940B2 (ja) 2024-02-29

Family

ID=77892014

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021578216A Active JP7440940B2 (ja) 2020-03-27 2021-03-27 Ｐｌｋ１の選択的分解誘導化合物
JP2023177565A Pending JP2023171659A (ja) 2020-03-27 2023-10-13 Ｐｌｋ１の選択的分解誘導化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023177565A Pending JP2023171659A (ja) 2020-03-27 2023-10-13 Ｐｌｋ１の選択的分解誘導化合物

Country Status (6)

Country Link
US (5) US20230158158A1 (cg-RX-API-DMAC10.html)
EP (1) EP3911654A4 (cg-RX-API-DMAC10.html)
JP (2) JP7440940B2 (cg-RX-API-DMAC10.html)
KR (8) KR102313753B1 (cg-RX-API-DMAC10.html)
CN (1) CN113784969A (cg-RX-API-DMAC10.html)
WO (4) WO2021194318A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023171659A (ja) * 2020-03-27 2023-12-01 オップテラ インコーポレイテッド Ｐｌｋ１の選択的分解誘導化合物

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020356484A1 (en) 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
TW202317546A (zh) 2021-07-09 2023-05-01 美商普萊克斯姆公司 調節ikzf2之芳基化合物及醫藥組合物
JP7555155B2 (ja) * 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物
WO2023016518A1 (zh) 2021-08-11 2023-02-16 四川海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
CN114380682A (zh) * 2021-10-27 2022-04-22 上海毕得医药科技股份有限公司 一种2,3-二氟-4-甲氧基苯乙酸合成方法
WO2023104195A1 (zh) * 2021-12-10 2023-06-15 正大天晴药业集团股份有限公司 一种异噻唑并[5,4-d]嘧啶类IRAK4抑制剂的制备方法
JP2024546115A (ja) * 2021-12-10 2024-12-17 シャンドン ルイ ファーマシューティカル カンパニー リミテッド プロテインキナーゼ阻害剤及びその製造方法と応用
CN116924929A (zh) * 2022-07-08 2023-10-24 重庆圣华曦药业股份有限公司 一种碘比醇异构体的合成方法
CN115490675B (zh) * 2022-09-19 2024-11-12 安阳师范学院 季酮酸衍生物及其制备方法与应用
CN120603831A (zh) * 2022-11-29 2025-09-05 厄普特拉株式会社 具有增加的刚性的plk1降解诱导化合物
WO2024153110A1 (zh) * 2023-01-17 2024-07-25 北京哲源科技有限责任公司 吡唑并喹唑啉类化合物的立体异构体和氘代衍生物及应用
EP4658658A1 (en) * 2023-02-02 2025-12-10 Uppthera, Inc. Novel plk1 degradation inducing compound
CN116554044A (zh) * 2023-05-16 2023-08-08 上海师范大学 一种无氨基保护的2,6-二异丙基-4-羧基苯胺及其合成方法
KR20250058831A (ko) 2023-10-23 2025-05-02 주식회사 펩토이드 Ｐｌｋ－１의 폴로박스 도메인에 결합하는 저분자 화합물을 함유하는 항암제
WO2025239662A1 (ko) * 2024-05-13 2025-11-20 (주) 업테라 분해 약물-항체 접합체용 plk1 분해 유도 화합물
CN119707950A (zh) * 2024-12-24 2025-03-28 无锡市南京大学锡山应用生物技术研究所 一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540463A (ja) 2007-09-25 2010-12-24 武田薬品工業株式会社 ポロ様キナーゼ阻害剤
JP2015508414A (ja) 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008003173A (es) * 2005-09-06 2008-03-18 Smithkline Beecham Corp Compuestos de bencimidazol-tiofeno como inhibidores de plk.
PL2125822T3 (pl) * 2006-12-21 2015-04-30 Nerviano Medical Sciences Srl Podstawione pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz
CN101636399B (zh) * 2007-03-22 2012-04-18 武田药品工业株式会社 可用作plk1抑制剂的取代的嘧啶并二氮杂*
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
AR076784A1 (es) * 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
BR112018008918A8 (pt) * 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
CN106543185B (zh) * 2016-11-10 2017-12-15 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
IL319363A (en) * 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
CN106977584B (zh) * 2017-04-19 2019-12-06 吉林大学 靶向泛素化降解plk1和brd4蛋白的化合物及其应用
WO2019114770A1 (zh) 2017-12-13 2019-06-20 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
KR102127289B1 (ko) * 2018-09-18 2020-06-26 고려대학교 산학협력단 암 세포를 표적화하기 위한 plk 선택적 형광 프로브 화합물 및 이를 포함하는 plk 검출용 형광 센서
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
CN109879877B (zh) 2019-03-04 2021-08-10 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
JP7555155B2 (ja) * 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540463A (ja) 2007-09-25 2010-12-24 武田薬品工業株式会社 ポロ様キナーゼ阻害剤
JP2010540464A (ja) 2007-09-25 2010-12-24 武田薬品工業株式会社 ポロ様キナーゼ阻害剤
JP2015508414A (ja) 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN, S. et al，Identification of novel, potent and selective inhibitors of Polo-like kinase 1，Bioorganic & Medicinal Chemistry Letters，2012年，Vol.22，pp.1247-1250
MU X. et al，Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells，Biochemical and Biophysical Research Communications，2019年11月07日，Vol.521，pp.833-839
ZENGERLE, M. et al，Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4，ACS Chem. Biol.，2015年，Vol.10，pp.1770-1777

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023171659A (ja) * 2020-03-27 2023-12-01 オップテラ インコーポレイテッド Ｐｌｋ１の選択的分解誘導化合物

Also Published As

Publication number Publication date
KR102337029B1 (ko) 2021-12-09
EP3911654A4 (en) 2022-05-11
KR20210150341A (ko) 2021-12-10
US20230372498A1 (en) 2023-11-23
JP2022539579A (ja) 2022-09-12
JP2023171659A (ja) 2023-12-01
WO2021194318A1 (en) 2021-09-30
WO2021194320A1 (en) 2021-09-30
EP3911654A1 (en) 2021-11-24
KR20210122165A (ko) 2021-10-08
US20230203006A1 (en) 2023-06-29
US20230104076A1 (en) 2023-04-06
CN113784969A (zh) 2021-12-10
KR102313753B1 (ko) 2021-10-19
KR20210122164A (ko) 2021-10-08
US12403198B2 (en) 2025-09-02
WO2021194319A1 (en) 2021-09-30
KR102313752B1 (ko) 2021-10-19
US20230159515A1 (en) 2023-05-25
KR20210122162A (ko) 2021-10-08
WO2021194321A1 (en) 2021-09-30
US11833208B2 (en) 2023-12-05
KR20210122163A (ko) 2021-10-08
KR102319264B1 (ko) 2021-11-01
KR102529222B1 (ko) 2023-05-08
US20230158158A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
KR102529222B1 (ko) Plk1 선택적 분해 유도 화합물
CN116261458B (zh) Plk1降解诱导化合物
JP7443425B2 (ja) αｖβ６インテグリン阻害剤
EP3538526B1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
CN112262139B (zh) 作为激酶抑制剂的氨基吡咯并三嗪
KR20220102156A (ko) Bcl6 표적화 모이어티에 연결된 e3 유비퀴틴 리가아제 결합 모이어티를 함유하는 이기능성 분자
CN115335381A (zh) 白细胞介素-1受体相关激酶的双功能降解剂及其治疗用途
KR20230130752A (ko) 단백질분해 조절제 및 연관된 사용 방법
CN106458976B (zh) 用于治疗疾病诸如糖尿病的吡咯烷gpr40调节剂
WO2004080966A1 (ja) 含窒素複素環誘導体およびそれらを有効成分とする薬剤
MX2015006038A (es) Moduladores de pirrolidina del receptor acoplado a la proteina g (gpr40).
KR102337040B1 (ko) HMG-CoA 환원효소 분해 유도 화합물
KR20230083276A (ko) 오토탁신 억제제 화합물
CN117794936A (zh) 新型plk1降解诱导化合物
HK40088882A (en) Autotaxin inhibitor compounds
HK40083579A (en) Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230317

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231013

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240208

R150 Certificate of patent or registration of utility model

Ref document number: 7440940

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150